Advertisement

Central European Journal of Medicine

, Volume 7, Issue 5, pp 599–603 | Cite as

Macrophages, TGF-β1 expression and iron deposition in development of NASH

  • Julian Ananiev
  • Mariana Penkova
  • Georgi Tchernev
  • Maya Gulubova
Research Article
  • 99 Downloads

Abstract

A wide range of molecular markers and different types of cells in liver are possible factors for progression of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) development of liver fibrosis. We investigated biopsies from 57 patients with NASH. The material was obtained from livers and was proceed immunohistochemistry antibodies against CD68 and TGF-beta 1. In addition, biopsies were evaluated for iron content. Macrophages/-positive/could be found in all 57 cases. The number of macrophages in the sinusoids correlated with the degree of portal fibrosis:64.% of the patients with mild or intensive fibrosis had high infiltration with CD68-positive cells, while 100% of the patients without fibrosis hadlow infiltration (χ2=8.56; p=0.003). In specimens we, 69.% of patients with different degree of fibrosis expressed TGF-β1 in their portal tracts, and 100% of patients without fibrosis did demonstrate expression of the protein (χ2=23.7; p<0.001). Hepatic iron was found in 100% (9) of patients with intensive fibrosis vs. 10.3% of the patients mild fibrosis (χ2=23.4; p<0.001). Our results suggest that the macrophages and macrophage-derived TGF-beta1 are the major factors responsible for development of fibrosis and progression of chronic liver disease.

Keywords

NASH CD68 TGF-beta1 Iron 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005; 42(5):987–1000PubMedCrossRefGoogle Scholar
  2. [2]
    Willner I.R., Waters B., Patil S.R., Reuben A., Morelli J., Riely C.A. Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96(10):2957–2961PubMedCrossRefGoogle Scholar
  3. [3]
    Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5):450–455. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-a or adiponectin? Hepatology 2004; 40(1):46–54PubMedCrossRefGoogle Scholar
  4. [4]
    Moirand R., Mortaji A.M., Loréal O., Paillard F., Brissot P., Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349:95–97PubMedCrossRefGoogle Scholar
  5. [5]
    Moirand R., Jouanolle A.M., Brissot P., Le Gall J.Y., David V., Deugnier Y. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116(2):372–377PubMedCrossRefGoogle Scholar
  6. [6]
    Nelson J.E., Bhattacharya R., Lindor K.D., et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007; 46: 723–729PubMedCrossRefGoogle Scholar
  7. [7]
    Bissell D.M., Roulot D., George J. Transforming growth factor-b and the liver. Hepatology 2001; 34: 859–867PubMedCrossRefGoogle Scholar
  8. [8]
    Jonsson J.R., Clouston A.D., Ando Y., Kelemen L.I., Horn M.J., et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148–155PubMedCrossRefGoogle Scholar
  9. [9]
    Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., et al. Nonalcoholic Steatohepatitis Clinical Research Network: Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313–1321PubMedCrossRefGoogle Scholar
  10. [10]
    Bissell D.M., Wang S.S., Jarnagin W.R., Roll F.J. Cell specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine of hepatocyte proliferation. J Clin Invest 1995; 96: 447–455Google Scholar
  11. [11]
    Bissell D.M., Roulot D., George J. Transforming growth factor-b and the liver. Hepatology 2001; 34: 859–867PubMedCrossRefGoogle Scholar
  12. [12]
    Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-b in hepatic fibrosis. Front Biosci 2002; 7: d793–807PubMedCrossRefGoogle Scholar
  13. [13]
    Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509–1523PubMedCrossRefGoogle Scholar
  14. [14]
    Videla L.A., Fernandez V., Tapia G., Varela P. Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals 2003;16:103–111PubMedCrossRefGoogle Scholar
  15. [15]
    Blendis L., Oren R., Halpern Z. NASH: can we iron out the pathogenesis? Gastroenterology 2000;118:981–983PubMedCrossRefGoogle Scholar
  16. [16]
    Chitturi S., George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18–25PubMedCrossRefGoogle Scholar
  17. [17]
    Kadiiska M.B., Burkitt M.J., Xiang Q.H., Mason R.P. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest 1995;96:1653–1657Google Scholar
  18. [18]
    Brown K.E., Dennery P.A., Ridnour L.A., et al. Effect of iron overload and dietary fat on induces of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003;23:232–234PubMedCrossRefGoogle Scholar
  19. [19]
    Cornejo P., Varela P., Videla L.A., Fernandez V. Chronic iron overload enhances inducible nitric oxide synthase expression in rat liver. Nitric Oxide 2005;13:54–61PubMedCrossRefGoogle Scholar
  20. [20]
    Sorrentino P., D’Angelo S., Ferbo U., Micheli P., Bracigliano A., et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009;50:351–357PubMedCrossRefGoogle Scholar
  21. [21]
    Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103–1109PubMedGoogle Scholar
  22. [22]
    Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–1362PubMedCrossRefGoogle Scholar
  23. [23]
    Chitturi S., Weltman M., Farrell G.C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36:142–149PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Julian Ananiev
    • 1
  • Mariana Penkova
    • 2
  • Georgi Tchernev
    • 3
  • Maya Gulubova
    • 1
  1. 1.Department of General and Clinical Pathology and Forensic Medicine, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  2. 2.Department of Internal medicine, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  3. 3.Department of Dermatology and Venerology, Medical FacultyTrakia UniversityStara ZagoraBulgaria

Personalised recommendations